RNA interference and nonviral targeted gene therapy of experimental brain cancer.
The human epidermal growth factor receptor (EGFR) plays an oncogenic role in solid cancer, including brain primary and metastatic cancers. Transvascular nonviral gene therapy in combination with EGFR-RNA interference (RNAi) represents a new therapeutic approach to silencing oncogenic genes in solid cancers. This is achieved with pegylated immunoliposomes (PIL) carrying short hairpin RNA expression plasmids driven by the U6 RNA polymerase promoter and directed to target EGFR expression by RNAi. The PIL is comprised of a mixture of known lipids containing polyethyleneglycol (PEG), which stabilizes the PIL structure in vivo in circulation. The tissue target specificity of PILs is given by conjugation of approximately 1% of the PEG residues to monoclonal antibodies (mAbs) that bind to specific endogenous receptors (i.e., insulin and transferrin receptors) located in the brain vascular endothelium, which forms the blood brain barrier (BBB), and brain cellular membranes, respectively. These mAbs are known to induce 1) receptor-mediated transcytosis of the PIL complex through the BBB and 2) transport to the brain cell nuclear compartment. Treatment of an experimental human brain tumor model in scid mice is possible with weekly intravenous RNAi gene therapy causing reduced tumor expression of EGFR and 88% increase in survival time of these mice with advanced intracranial brain cancer. The availability of additional RNAi tumor targets may improve the therapeutic efficacy of this new anticancer drug. The accessibility to chimeric and/or humanized mAbs directed to human BBB and brain cell specific-receptors may accelerate the application of this technology to the treatment of human tumors.
Boado
Ruben J
RJ
ArmaGen Technologies, Inc., Santa Monica, California 90401, USA. rboado@mednet.ucla.edu
D000818:Animals; D001932:Brain Neoplasms / Q000628:therapy*; D066246:ErbB Receptors / Q000187:drug effects; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000627:therapeutic use
D034741:RNA, Small Interfering; D066246:ErbB Receptors
Am J Pathol. 1992 Nov;141(5):1115-24
1443046
Neurology. 2004 Apr 27;62(8):1275-81
15111662
Clin Neuropathol. 1995 May-Jun;14(3):169-74
7671460
Nat Med. 1997 Dec;3(12):1354-61
9396605
Brain Res Mol Brain Res. 1998 Aug 15;59(1):109-13
9729315
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5515-20
11960009
Science. 2002 Apr 19;296(5567):550-3
11910072
Methods. 2002 Feb;26(2):199-213
12054897
Curr Treat Options Oncol. 2001 Dec;2(6):507-15
12057096
Cancer Res. 2002 Jun 15;62(12):3335-9
12067969
RNA. 2002 Jun;8(6):842-50
12088155
Mol Ther. 2002 Jul;6(1):67-72
12095305
Nat Rev Drug Discov. 2002 Feb;1(2):131-9
12120094
Nat Rev Genet. 2002 Oct;3(10):737-47
12360232
Clin Cancer Res. 2002 Nov;8(11):3496-502
12429640
Neuron. 2002 Nov 14;36(4):555-8
12441045
Front Biosci. 2003 Jan 1;8:e1-13
12456322
Science. 2002 Dec 20;298(5602):2296-7
12493875
Protein Expr Purif. 1999 Nov;17(2):183-202
10545267
Cancer. 2000 Feb 15;88(4):761-9
10679644
Pharm Res. 2000 Mar;17(3):266-74
10801214
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7503-8
10852962
J Neurochem. 2000 Oct;75(4):1575-82
10987838
Expert Opin Investig Drugs. 2000 Apr;9(4):713-26
11060704
Oncol Res. 2000;12(2):107-12
11132923
Endocr Relat Cancer. 2001 Jun;8(2):83-96
11397666
Cancer Res. 2001 Jul 15;61(14):5355-61
11454674
Exp Cell Res. 2001 Aug 15;268(2):262-73
11478852
J Gene Med. 2003 Feb;5(2):157-63
12539153
Hum Gene Ther. 2002 Dec 10;13(18):2197-201
12542850
Hum Gene Ther. 2003 Jan 1;14(1):1-12
12573054
Mol Ther. 2003 Jan;7(1):11-8
12573613
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Clin Cancer Res. 2004 Jun 1;10(11):3667-77
15173073
Science. 2004 Jun 4;304(5676):1497-500
15118125
J Neurosurg. 1989 Dec;71(6):826-36
2585073
J Neurosurg. 1991 Jan;74(1):27-37
1984503
J Cell Physiol. 1992 Jan;150(1):104-15
1346140
J Korean Med Sci. 2001 Aug;16(4):481-8
11511795
Acta Neuropathol. 2001 Jun;101(6):605-15
11515790
Neuro Oncol. 1999 Jan;1(1):44-51
11550301
Pharm Res. 2001 Aug;18(8):1091-5
11587478
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
11597399
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12754-9
11592987
J Gene Med. 2002 Mar-Apr;4(2):183-94
11933219
Genes Dev. 2002 Apr 15;16(8):948-58
11959843
Mol Ther. 2003 Feb;7(2):228-36
12597911
Int J Cancer. 2003 May 10;104(6):716-21
12640678
Lancet Oncol. 2003 Apr;4(4):198
12681250
Cancer Res. 2003 May 1;63(9):2300-5
12727853
Curr Oncol Rep. 2003 Jul;5(4):342-6
12781078
Cancer. 2003 Jun 15;97(12):2972-7
12784331
Lancet Oncol. 2003 Jul;4(7):397-406
12850190
Cancer J. 2003 May-Jun;9(3):222-9
12952307
Cancer Res. 2003 Oct 15;63(20):6962-70
14583498
J Gene Med. 2003 Dec;5(12):1039-45
14661179
Mayo Clin Proc. 2003 Dec;78(12):1529-36
14661682
Pharm Res. 2003 Nov;20(11):1779-85
14661922
Nucleic Acids Res. 2004;32(2):661-8
14754988
Hum Gene Ther. 2004 Apr;15(4):339-50
15053859
Oncogene. 1995 Apr 20;10(8):1545-52
7731709